Esperion Therapeutics Inc (NAS:ESPR)
$ 2.3524 0.0624 (2.72%) Market Cap: 445.69 Mil Enterprise Value: 476.24 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 55/100

Esperion Therapeutics Inc at Needham Healthcare Conference (Virtual) Transcript

Apr 12, 2022 / 01:30PM GMT
Release Date Price: $5.57 (-0.71%)
Serge Belanger
Needham & Company, LLC - Analyst

Good morning. Welcome to Needham's 21st annual healthcare conference. I'm Serge Belanger, one of the healthcare analysts at Needham. And we're proud to have for our next session, Esperion Therapeutics, and we have the company's CEO, Sheldon Koenig, to give us an overview about the company. And then we will jump into Q&A.

So Sheldon, I will hand it over to you to maybe give us a brief overview of Esperion.

Sheldon Koenig
Esperion Therapeutics, Inc. - President & CEO

Great. Thanks, Serge. And on behalf of Esperion and all the employees here, we really appreciate the opportunity to be here at the Needham conference. I realize it's virtual but I'm positive next year, we will probably be live. I think we said that last year as well. But we really appreciate the opportunity.

Esperion is a company that's really dedicated to cardiovascular medicine. We currently have two products that we are commercializing: NEXLIZET which is bempedoic acid plus ezetimibe; and NEXLETOL which is bempedoic

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot